Cardiff Oncology (CRDF) news
Recent news
Cardiff Oncology Q2 operating expenses USD 9.719 million
Cardiff Oncology, Inc. (Nasdaq: CRDF) reported operating expenses of $9.719 million for the second quarter of 2026, according to its most recent financial disclosures. This figure reflects the company’s ongoing investment in clinical development and operational activities as it advances its lead…
AInvest Wire · Aug 11, 2026Cardiff Oncology Q2 EPS USD -0.14
AInvest Wire · Aug 11, 2026Cardiff Oncology Inc <CRDF.O>: TD Cowen cuts to hold from buy
TD Cowen has downgraded Cardiff Oncology Inc (CRDF.O) from "Buy" to "Hold," citing a reduced price target and a reassessment of the company’s near-term prospects. The move reflects a broader trend of analysts recalibrating expectations amid ongoing delays in the execution of previously communicated…
AInvest Wire · Jun 1, 2026Cardiff Oncology Inc <CRDF.O>: H.C. Wainwright cuts to neutral from buy
Cardiff Oncology Inc : H.C. Wainwright cuts to neutral from buy
AInvest Wire · Jun 1, 2026ImportantCardiff Oncology surges 31% premarket on favorable data from cancer drug tials
AInvest Wire · Sep 27, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.